Cell: Major development, Chinese scientists reveal full map of lung adenocarcinoma proteomics for the first time

The !---- introduction: Lung cancer is one of the most common and death-threatening malignancyslung adenocarcinoma (LUAD) accounts for about half of all lung cancersrecently, scientists from the Chinese Academy of Sciences and other domestic institutions for the first time in the international community revealed the complete map of the lung adenocarcinoma proteomics, for the precision of lung adenocarcinoma provides valuable resourcesDespite significant progress in the genomics of lung adenocarcinoma (LUAD) in recent years, a large proportion of LUAD patients still lack targeted treatment strategiesbecause proteins are direct performers of life activity, a comprehensive proteomic study of LUAD can fill the knowledge gap between genomic abnormalities and cancer-causing protein functionrecently, scientists from several domestic institutions, such as the Chinese Academy of Sciences, revealed for the first time the complete map of the proteomics of lung adenocarcinoma, which provides valuable resources for the precision medicine of lung adenocarcinomathe study revealed luAD-related molecular characteristics, its association with clinical results, potential prognostic biomarkers and drug targets through a comprehensive analysis of sequencedata from proteomics, phosphorylation proteomics, transcription groups, and omniexal subgroup, and published online July 9 in Cellentitled "Integrative Proteomicization of Human Shuman Lung Adenocarcinoma" In order to fully understand the molecular structure of LUAD and provide the basis for more accurate diagnosis and treatment of LUAD, the scientists conducted proteomics and phosphonate proteomics analysis of tumor tissue and their corresponding non-cancerous adjacent tissues in 103 luAD patients in this studyA total of 11,119 proteins and 22,564 phosphorylation sites were identifiedcombine these proteomic data with clinical information and genomics data to obtain a comprehensive molecular map of LUADgraphic abstract scientists have found that epithelial-interstitial transformation, as well as inflammatory and carcinogenic signaling pathways, are likely to lead to adverse prognosis of Stage I LUADthey further established a link between genetic changes and proteomic characteristics in patients with EGFR or TP53 mutations, the two main driver genes in Chinese LUAD patientsin patients with EGFR mutations, increased expression levels of proteins in two histological markers, TTF-1 and Napsin-A, as well as splicingsignificant changes in a variety of cancer-causing pathways, including DNA replication and mismatch repair, occurred in patients with TP53 mutationsresearchers divided all patients into three proteomic subtypes (S-I, S-II, S-III), each with unique molecular and clinical characteristicscomprehensive bioinformatics analysis showed that S-I patients were associated with cellular environment and good prognosis, in contrast, patients with S-III were associated with cell proliferation and proteomic stability and poor prognosisphosphoric acid proteomicanalysis analysis further reveals the signaling pathways and kinases activated in different proteomic subtypessynthesis of proteomic data and clinical data further revealed 27 potential plasma biomarkers and luAD multiple drug targets, the researchers noted that HSP 90 beta is one of the potential biomarkers and has been further validated in a separate queuethis work provides new insights into LUAD research, beyond current genomic researchChinese scientists have carried out large-scale, high-throughput, systematic panoramic proteomics research on lung adenocarcinoma for the first time in the world, and established a complete map of LuAD in China at the levels of genomics, transcriptomics, proteomics and phosphorylationthis proteomic data set as a valuable and powerful resource to accelerate the transformation of basic research into more accurate diagnosis and treatment in clinical practice